Selected article for: "antimicrobial susceptibility and secondary treatment"

Author: Khurana, Surbhi; Singh, Parul; Sharad, Neha; Kiro, Vandana V.; Rastogi, Neha; Lathwal, Amit; Malhotra, Rajesh; Trikha, Anjan; Mathur, Purva
Title: Profile of co-infections & secondary infections in COVID-19 patients at a dedicated COVID-19 facility of a tertiary care Indian hospital: Implication on antimicrobial resistance
  • Cord-id: u6folu00
  • Document date: 2020_11_16
  • ID: u6folu00
    Snippet: BACKGROUND: The COVID-19 pandemic has raised concerns over secondary infections because it has limited treatment options and empiric antimicrobial treatment poses serious risks of aggravating antimicrobial resistance (AMR). Studies have shown that COVID-19 patients are predisposed to develop secondary infections. This study was conducted to ascertain the prevalence and profiles of co- & secondary infections in patients at the COVID-19 facility in North India. METHODS: We studied the profile of p
    Document: BACKGROUND: The COVID-19 pandemic has raised concerns over secondary infections because it has limited treatment options and empiric antimicrobial treatment poses serious risks of aggravating antimicrobial resistance (AMR). Studies have shown that COVID-19 patients are predisposed to develop secondary infections. This study was conducted to ascertain the prevalence and profiles of co- & secondary infections in patients at the COVID-19 facility in North India. METHODS: We studied the profile of pathogens isolated from 290 clinical samples. Bacterial and fungal pathogens were identified, and antimicrobial susceptibility was determined by the Vitek2® system. Additionally, respiratory samples were tested for any viral/atypical bacterial co-infections and the presence of AMR genes by FilmArray test. The clinical and outcome data of these patients were also recorded for demographic and outcome measures analyses. RESULTS: A total of 151 (13%) patients had secondary infections, and most got infected within the first 14 days of hospital admission. Patients aged >50 years developed severe symptoms (p = 0.0004) and/or had a fatal outcome (p = 0.0005). In-hospital mortality was 33%.K.pneumoniae (33.3%) was the predominant pathogen, followed by A. baumannii (27.1%). The overall resistance was up to 84%.Majority of the organisms were multidrug-resistant (MDR) harbouring MDR genes. CONCLUSION: A high rate of secondary infections with resistant pathogens in COVID-19 patients highlights the importance of antimicrobial stewardship programs focussing on supporting the optimal selection of empiric treatment and rapid-de-escalation, based on culture reports.

    Search related documents:
    Co phrase search for related documents
    • acinetobacter baumannii and acute respiratory distress syndrome: 1, 2, 3, 4, 5
    • acinetobacter baumannii and los stay length: 1, 2, 3
    • acinetobacter klebsiella pneumoniae and acute respiratory: 1, 2, 3, 4, 5, 6, 7
    • acinetobacter klebsiella pneumoniae and acute respiratory distress syndrome: 1, 2
    • acinetobacter klebsiella pneumoniae and los stay length: 1
    • actual burden and acute respiratory: 1, 2, 3, 4, 5, 6, 7
    • actual burden and acute respiratory distress syndrome: 1
    • acute respiratory and los stay length: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress syndrome and los stay length: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15